This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Morphic Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Morphic HoldingDer Gewinn des Unternehmens wird voraussichtlich um 8.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 76.5% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 2.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -71.2% betragen.

Wichtige Informationen

-6.4%

Wachstumsrate der Gewinne

-0.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	81.5%
Zukünftige Eigenkapitalrendite	-87.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	07 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Jun 26

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

Nov 03

Morphic: Pioneering Integrin Medicines

Oct 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:MORF - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1	-251	-203	-195	7
12/31/2025	1	-232	-191	-179	9
12/31/2024	0	-213	-173	-162	10
6/30/2024	N/A	-180	-138	-136	N/A
3/31/2024	N/A	-161	-129	-127	N/A
12/31/2023	1	-152	-114	-112	N/A
9/30/2023	7	-136	-110	-109	N/A
6/30/2023	9	-130	-106	-104	N/A
3/31/2023	69	-64	-105	-104	N/A
12/31/2022	71	-59	-101	-101	N/A
9/30/2022	74	-56	-97	-96	N/A
6/30/2022	75	-51	-97	-96	N/A
3/31/2022	19	-106	-92	-91	N/A
12/31/2021	20	-96	-84	-83	N/A
9/30/2021	16	-92	-78	-77	N/A
6/30/2021	39	-61	-49	-49	N/A
3/31/2021	43	-50	-48	-47	N/A
12/31/2020	45	-45	-47	-46	N/A
9/30/2020	39	-47	-47	-46	N/A
6/30/2020	19	-61	-65	-63	N/A
3/31/2020	17	-55	-63	-61	N/A
12/31/2019	17	-43	-44	-42	N/A
9/30/2019	21	-29	63	65	N/A
6/30/2019	15	-27	72	73	N/A
3/31/2019	9	-24	81	82	N/A
12/31/2018	3	-24	76	76	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MORF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MORF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MORF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MORFDie Einnahmen des Unternehmens (76.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: MORFDie Einnahmen des Unternehmens (76.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MORF wird voraussichtlich in 3 Jahren unrentabel sein.

This company has been acquired

Morphic Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 88%, EPS upgraded

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Price target decreased by 13% to US$65.38

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Price target decreased to US$83.80

General Counsel & Secretary exercised options to buy US$827k worth of stock.

Price target decreased to US$95.00

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

CFO & COO exercised options and sold US$246k worth of stock

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

CFO & COO exercised options and sold US$1.3m worth of stock

Morphic: Pioneering Integrin Medicines

Chief Scientific Officer notifies of intention to sell stock

Founder recently bought US$4.2m worth of stock